Molecular Subtyping Bests Standard in Predicting Breast Cancer Outcomes
Molecular tumor subtyping offers more accurate prediction of long-term breast cancer outcomes.
Diagnosis & Disease Information
Neoadjuvant Veliparib Plus Carboplatin Holds Promise for TNBC
Adaptive randomization study finds neoadjuvant veliparib plus carboplatin may improve pCR in TNBC.
Switching Chemo Regimen After Cycle 1 Not Beneficial in Metastatic Breast Cancer
Patients with metastatic breast cancer did not benefit from switching to a second-line chemotherapy regimen after one cycle of first-line therapy.
Ramucirumab Does Not Improve Survival in Advanced Breast Cancer
Adding ramucirumab to docetaxel does not improve survival among patients with HER2-negative, advanced breast cancer.
Neoadjuvant Carboplatin, Bevacizumab Improve pCR Rates in TNBC
Adding carboplatin or bevacizumab to standard chemotherapy improves pCR in TNBC.
Bisphosphonate Not Beneficial for Chemoresistant Breast Cancer
Zoledronate does not improve survival rates among women with chemoresistant breast cancer.
Locoregional Treatment After Chemo Not Recommended for Metastatic Breast Cancer
Women with metastatic breast cancer who respond to chemotherapy should not receive locoregional treatment.
Benefits of Mammography Screening Consistent Across Studies
Reviews show a substantial reduction in breast cancer mortality with screening.
PIK3CA Mutations Implicated in Treatment-Resistance for Some Breast Cancers
Some breast tumors resistance to chemotherapy and HER2-targeted therapy is associated with PIK3CA mutations.
Combo Dasatinib/Letrozole Delays Disease Progression in Some Breast Cancers
Dasatinib plus letrozole delays disease progression in some advanced breast cancers.
- Loading...
Loading...
Next post in SABCS 2013
Loading... 
Loading...